Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Cancer research now generates huge amounts of data, and sophisticated computational tools are needed to answer biological questions. Making sense of this variability at the molecular level will help us better tailor treatments to individual cancer patients.

Q: What is bioinformatics?

Benjamin Schuster-Böckler: Bioinformatics is a fairly new field of research that tries to answer biological questions using computers or computational tools. Over the last 20 years or so there has been a revolution in the biological sciences with new experimental techniques that produce huge amounts of data. For one cancer patient you would produce so much data that it would take you a whole day to download on your home internet. We don't have only one of these data sets, but thousands. It really is almost impossible now to do research without using computer programs to actually sift through that data to find the biologically relevant aspects and distinguish them from random noise.

Q: What are the most important lines of research that have developed in the last five to ten years?

BS: What I find particularly striking that has come out of the genomics revolution in the last five or ten years, is that we are now aware that cancer is an incredibly diverse disease. It's almost as if it is not just one disease but many diseases. Each patient can have very similar presentation in the clinic, but if you look at the molecular details and the genomes, these patients can be incredibly different. It is really becoming clearer that those differences can have a great impact on the treatment success of these patients. This field known as cancerheterogeneity is one of the things that I have found particularly exciting.

Q: How is bioinformatics helping us understand cancer?

BS: Nowadays with the explosion of data that is being generated in cancer research, it is almost not a question of how it can help us understand cancer, but it is almost impossible to do any cancer research without the help of computer tools. To put this into perspective, it is very common nowadays to generate data sets which have millions of rows and tens or thousands of columns, and just by looking at them you would not be able to understand what they mean. We really need computer programs to help us detect the biologically relevant aspects of the result and distinguish them from those aspects which are effectively noise.

Q: Can you tell us about your research?

BS: The research in my group is focussed on trying to understand the origins of variability in cancer. To explain it better I can use an analogy. A mutation in the genome is like a car accident that happens on a stretch of road; but not all roads are equally dangerous. Even though each accident might be bad luck, the frequency of accidents varies massively between different roads. What we are trying to understand is the specific likelihood of an accident is in a particular area on average. The important question is whether there are specific roads where accidents happen with a far greater frequency than on average. Those are the regions that are of particular importance for disease. In the genomic context, there are some regions in the genome which accumulate mutations at a much greater rate than similar other regions in the genome that have similar characteristics and these are the ones that we want to identify.

Q: Why does this research matter and why should we put money into it?

BS: We can see now that patients with cancer are very different on the genomic level. It is crucial for us to understand which ones of the mutations in the patient genomes are driving the cancer, the ones that are important for the development and the progression of the disease, and distinguish them from those variations which are just passengers. In order to be able to distinguish those drivers from the passengers we need to have an idea of what the overall likelihood of mutations is in the genome on average. That will allow us to pinpoint those mutations that happen at much greater frequency and those ones are usually the ones which are relevant in the disease context.

Q: How does your research fit into translational medicine within the Department?

BS: I think it is generally accepted that in the future we will see a lot more personalised medicine. When I say personalised medicine, I mean that we will start tailoring treatment to an individual patient's genomic characteristics. In order to be able to do that we need to understand which aspects of an individual's genome are predictive for treatment success and which ones have absolutely no impact on the disease. So, one of the key aspects of the research that we are doing in our lab is helping to make that distinction.

Benjamin Schuster-Böckler

Dr Benjamin Schuster-Böckler heads the computational group at the Ludwig Institute for Cancer Research. His work has demonstrated that epigenetic modifications influence the mutational landscape in cancer cells. He studies the effects of DNA-binding proteins on transcription factors, with the aim to understand the regulation (and mis-regulation) of the transcription of important oncogenes and tumour suppressors.

More podcasts related to Cancer

Raghib Ali: INDOX Cancer Research Network

INDOX is a collaboration between Oxford and twelve leading cancer centres in India. It aims to develop effective and affordable cancer treatments in low and middle income countries, to improve the early detection of cancer, and to reduce the incidence of cancer by establishing the population specific risk factors.

Vincenzo Cerundolo: Cancer immunology

The development of therapeutic vaccines is more challenging. Current lines of research include the development of antibodies blocking inhibitory T cell signals, and the characterisation of adjuvants.

David Jackson: The Lymphatic System in Immunity and Cancer

Our lymphatic system protects us against pathogens: it collects micro-organisms and carries them to the lymph nodes where they will meet and activate T cells and B cells. Cancer cells also migrate to the lymph nodes, but instead of activating the immune system they actually suppress it. A better understanding of these mechanisms might help us better control the spread of tumours, and also block unwanted immune responses in autoimmune diseases, block tissue rejection and make vaccines more effective.

Tim Key: Role of Lifestyle and Diet in Cancer

We know that although smoking is still the most important cause of cancer, obesity and high intakes of alcohol increase the risk for several types of cancer. The role of diet in the development of cancer is much less clear, but there is a lot of evidence suggesting that diet does matter.

Patrick Pollard: Cancer Metabolism

Dr Pollard’s work is focused on a form of kidney cancer for which no effective therapy exists once it metastasizes. By integrating analyses of these cancer cells and novel models he hopes to provide insights into altered cancer metabolism and a real, innovative route into the design of therapies for various cancers.

Catherine Green: DNA replication and Cancer

The process of DNA replication is complex, and mistakes can lead to genome instability. Surveillance systems are not always successful which results in mutations that have the potential to inactivate genes or change their activity. This can lead to cancer, and many chemotherapeutic drugs are designed to disrupt DNA replication. A better understanding of these mechanisms can help us develop new drugs with reduced side effects.

Skirmantas Kriaucionis: Epigenetic modifications and cancer

Although all cells in our body have the same genome, they look different and perform different functions. Epigenetic modifications such as methylations ensure which sets of genes are expressed in specific cells and how this specificity is inherited. Cancer cells show particular epigenetic abnormalities which can be targeted for cancer therapies.

Ross Chapman: Repairing DNA damage

Whilst controlled DNA breaks allow for our vast repertoire of antibodies, DNA damage happening out of context can lead to cancer or predisposition to cancer. Recent developments in personalised medicine exploit the DNA repair weaknesses of cancer cells to selectively kill them. A better understanding of the underlying mechanisms can help develop innovative and targeted therapies.

John Christianson: Cleaning up misfolded proteins

Misfolded proteins can either create the loss of a cellular function, or escape degradation, causing aggregation diseases. Better knowledge of these mechanisms helps us understand the root cause of different kind of diseases, and also develop targets for therapeutic intervention.

Robert Gilbert: Targeting cancer mechanisms

Switching mechanisms within our cells are in part responsible for their development. MicroRNAs control a whole set of proteins associated with stem cell biology, particularly cancer stem cells. Targeting these components raises the potential for new anti-cancer therapeutics, which work by switching off protein production rather than inhibiting them later.

Translational Medicine

From Bench to Bedside

Ultimately, medical research must translate into improved treatments for patients. At the Nuffield Department of Medicine, our researchers collaborate to develop better health care, improved quality of life, and enhanced preventative measures for all patients. Our findings in the laboratory are translated into changes in clinical practice, from bench to bedside.